Summary of TEAEs following IV administration of AB002
| . | AB002 . | Pooled placebo . | Total . |
|---|---|---|---|
| Trial participants, n | 16 | 5 | 21 |
| Trial participants with TEAE, n (%) | 3 (19) | 1 (20) | 4 (19) |
| Total TEAE, n | |||
| Mild | 2 | 3 | 5 |
| Moderate | 2 | 1 | 3 |
| Severe | 0 | 0 | 0 |
| Relationship to study drug, n | |||
| Unrelated | 3 | 4 | 7 |
| Unlikely | 0 | 0 | 0 |
| Possibly | 1 | 0 | 1 |
| Probably | 0 | 0 | 0 |
| Likely | 0 | 0 | 0 |
| Most common TEAE, n | |||
| Generalized headache | 2 | 0 | 2 |
| Possibly treatment-related TEAE, n | |||
| Generalized headache | 1 | 0 | 1 |
| . | AB002 . | Pooled placebo . | Total . |
|---|---|---|---|
| Trial participants, n | 16 | 5 | 21 |
| Trial participants with TEAE, n (%) | 3 (19) | 1 (20) | 4 (19) |
| Total TEAE, n | |||
| Mild | 2 | 3 | 5 |
| Moderate | 2 | 1 | 3 |
| Severe | 0 | 0 | 0 |
| Relationship to study drug, n | |||
| Unrelated | 3 | 4 | 7 |
| Unlikely | 0 | 0 | 0 |
| Possibly | 1 | 0 | 1 |
| Probably | 0 | 0 | 0 |
| Likely | 0 | 0 | 0 |
| Most common TEAE, n | |||
| Generalized headache | 2 | 0 | 2 |
| Possibly treatment-related TEAE, n | |||
| Generalized headache | 1 | 0 | 1 |